Benefits
Recurrent UTI prevention in women (FDA-acknowledged)
In a 6-month multicenter randomized, double-blind, placebo-controlled trial in 150 females aged 18 to 65 with a history of recurrent UTIs, one 500 mg capsule a day of whole cranberry powder (Pacran) reduced the risk of a urine-culture-confirmed UTI by 52% compared with placebo (adjusted relative risk 0.48, 95% CI 0.26 to 0.87, p=0.01) and lengthened the time to a first UTI (hazard ratio 0.36, p=0.01). The same trial found no significant difference in symptomatic suspected UTIs, so the effect showed up in laboratory-confirmed infections rather than in symptoms alone. An earlier 6-month trial in 176 sexually active women reported fewer women having at least one UTI on Pacran than on placebo (10.8% versus 25.8%); that trial is not among the studies referenced on this page. The FDA allows only a qualified health claim here, the category it uses when supporting evidence is limited.
Culture-confirmed UTI reduction
The 2025 trial (150 females, 6 months) used urine culture rather than self-report to confirm infections. Culture-confirmed UTI risk was 52% lower on Pacran (adjusted relative risk 0.48, 95% CI 0.26 to 0.87, p=0.01), mean total UTIs were about 59% lower (incidence rate ratio 0.41, p=0.01) and E. coli UTIs were roughly halved (relative risk 0.49, p=0.05). Two things to be straight about: symptomatic suspected UTIs and culture-confirmed dysuria did not differ significantly between the groups, and this is one industry-funded trial rather than a body of independent replication.
Anti-adhesion mechanism (well-characterized)
The leading explanation is that cranberry's A-type proanthocyanidins (PACs) make it harder for E. coli to stick to the cells lining the urinary tract, so more bacteria get flushed out with normal urination. This comes from laboratory and urine-sample work, not from human outcome trials, so treat it as a plausible explanation for the trial results rather than something proven in people. Cranberry is not an antibiotic and does not kill bacteria.
Whole-fruit vs PAC-extract approach
Pacran uses the whole cranberry fruit (not just PAC-isolated extract). This delivers the whole fruit's mix of compounds: PACs plus anthocyanins, organic acids such as benzoic and quinic acid, and other phenolics. Whether the whole fruit works better than an isolated PAC extract is an open question. A 2015 six-month randomized trial in women asked directly whether a high proanthocyanidin content is what makes cranberry work, and the question is still unsettled. Treat whole-fruit superiority as a hypothesis, not an established advantage.
Safety in long-term use
In the 6-month trial the investigators reported no safety concerns, and no significant differences from placebo in blood chemistry, blood counts or urinalysis. That covers 6 months of daily use in adults; longer-term data are limited. Decisions about preventing repeat infections, including whether preventive antibiotics are appropriate, belong with your clinician, and cranberry should not be used in place of a prescribed treatment.
Convenient single capsule daily
Unlike cranberry juice, which means drinking a large volume every day and often comes with added sugar, Pacran provides the amount used in the trials in one 500 mg capsule a day. That makes a 6-month daily routine easier to stick with, though convenience is a practical point and not itself evidence of benefit.
Mechanism of action
A-type proanthocyanidin anti-adhesion
Cranberry contains both A-type and B-type proanthocyanidins. The A-type linkages are characteristic of cranberry, and they are the ones researchers think matter. In laboratory work they interfere with the hair-like fimbriae that E. coli uses to attach to the cells lining the urinary tract. B-type PACs (common in many plants) lack this specific anti-adhesion activity.
Reduced biofilm formation
In laboratory studies, PACs may interfere with E. coli biofilm formation. This has not been shown to happen in people. Established biofilms are difficult to clear and contribute to recurrent infections; preventing initial adhesion is key to preventing biofilm establishment.
Acidification (modest contribution)
Cranberry's organic acids (benzoic, quinic, hippuric) historically were thought to acidify urine and inhibit bacterial growth. Modern research indicates this is a minor contributor — the anti-adhesion effect of PACs appears far more important than pH effects.
Hippuric acid antimicrobial effect
Cranberry quinic acid is metabolized to hippuric acid, which has weak antimicrobial activity in urine. Considered a minor mechanism contributor rather than primary action.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 176 sexually active women with history of recurrent UTI (≥2 symptomatic UTIs in previous 12 months). Intervention: 500 mg/day Pacran or placebo for 6 months.
176 sexually active women with at least 2 symptomatic UTIs in the previous 12 months.
Randomized, double-blind, placebo-controlled trial in 176 sexually active women with history of recurrent UTI (≥2 symptomatic UTIs in previous 12 months). Intervention: 500 mg/day Pacran or placebo for 6 months. Reported outcome: 10.8% of the Pacran group had at least one UTI versus 25.8% on placebo (p=0.04), with a longer time to a first UTI. Limitations worth knowing: this trial is not among the references listed on this page, so its details are not verified here, and it counted reported infections rather than using the urine-culture endpoint of the larger 2025 trial. Cranberry supplements carry only an FDA qualified health claim, the category the FDA uses when the evidence is limited.
Multicenter 6-month randomized double-blind placebo-controlled trial in 150 healthy women with recurrent UTI.
150 healthy women with recurrent UTI
Multicenter 6-month randomized double-blind placebo-controlled trial in 150 healthy women with recurrent UTI. Primary outcome: culture-confirmed UTIs (>10⁸ CFU/L) rather than self-reported UTIs — eliminating self-report bias. Result: culture-confirmed UTI risk was 52% lower on Pacran than on placebo (adjusted relative risk 0.48, 95% CI 0.26 to 0.87, p=0.01), E. coli UTIs were about half as common (relative risk 0.49, p=0.05), time to a first UTI was longer (adjusted hazard ratio 0.36, p=0.01) and mean total UTIs were lower (incidence rate ratio 0.41, p=0.01). Nulls reported in the same paper: no significant difference in symptomatic suspected UTIs or in culture-confirmed dysuria. No safety concerns were reported. Published in the American Journal of Clinical Nutrition in 2025 (Stonehouse and colleagues, PMID 39863114); the study was industry funded.